Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Ulviprubart by Abcuro for Inclusion Body Myositis (IBM): Likelihood of Approval
Ulviprubart is under clinical development by Abcuro and currently in Phase III for Inclusion Body Myositis (IBM). According to GlobalData,...